Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Role of telavancin in treatment of skin and skin structure infections. Clin Cosmet Investig Dermatol 2010 Oct 07;3:127-33

Date

01/01/2010

Pubmed ID

21437067

Pubmed Central ID

PMC3047943

DOI

10.2147/CCID.S9027

Abstract

Skin and skin structure infections (SSSIs) are a common diagnosis encountered by ambulatory and inpatient practitioners across the country. As the SSSIs become more complicated, they require increased health care resources and often involve hospitalization and intravenous antimicrobials. Complicated SSSIs are caused by a variety of pathogens, including Gram-positive, Gram-negative, and anerobic bacteria. Empiric broad-spectrum antibiotic coverage is warranted, taking into account area disease-state epidemiology and antimicrobial susceptibility data. Telavancin is an antimicrobial agent with a broad Gram-positive spectrum of activity which was recently approved for the treatment of SSSIs. It may especially benefit patients with resistant organisms, such as methicillin-resistant Staphylococcus aureus. This article reviews telavancin and its pharmacology, efficacy, and safety data to enhance the practitioner's knowledge base on the appropriateness of telavancin for the treatment of SSSIs.

Author List

Bonkowski J, Daniels AR, Peppard WJ

Author

William J. Peppard PharmD Trauma/Surgical Critical Care Pharmacist in the Pharmacy department at Froedtert Hospital




jenkins-FCD Prod-388 89e904233d719332173309c68ab82b0b2a78a3a7